PubMed · 11453712
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
R A Kazin, N R Lowitt, M H Lowitt. 2001-07-17. Update in dermatology.. https://doi.org/10.7326/0003-4819-135-2-200107170-00013
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
In 1997, a new DNA virus, designated TTV "Transfusion Transmitted Virus", was isolated and seemed to be associated with non A-G post-transfusion hepatitis. The virus infects mainly patients at risk for parenteral exposure and hence, prone to develop chronic liver disease, as well as healthy populations worldwide. Few reports, however, have been published on the epidemiology and potential significance of TTV infection in patients with renal disease. This paper reviews, characterization of the virus, the history of its discovery, taxonomy and identification. Current status of TTV infection in patients with renal diseases are also summarised.
To achieve high immunization levels among populations indicated to receive hepatitis A and/or B vaccine, strategies must be implemented to integrate vaccination into routine medical care. Such strategies must address the educational needs and communication skills of providers, patients' awareness of the diseases and the vaccines, the complexity of existing office systems, documentation issues including the use of immunization registries, reimbursement and third-party coverage issues, and ongoing office-based quality assurance. This article describes office-based approaches to implementing hepatitis vaccination programs and some of the tools available to facilitate this process.
Explore the source record for details and available documents.